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Postpartum diabetes screening among low
income women with gestational diabetes
in Missouri 2010–2015
Cynthia J. Herrick1,2* , Matthew R. Keller3, Anne M. Trolard4, Ben P. Cooper5, Margaret A. Olsen3
and Graham A. Colditz2
Abstract
Background: Gestational diabetes increases risk for type 2 diabetes seven-fold, creating a large public health
burden in a young population. In the US, there are no large registries for tracking postpartum diabetes screening
among women in under-resourced communities who face challenges with access to care after pregnancy. Existing
data from Medicaid claims is limited as women often lose this coverage within months of delivery. In this study, we
aim to leverage data from electronic health records and administrative claims to better assess postpartum diabetes
screening rates among low income women.
Methods: A retrospective population of 1078 women with gestational diabetes who delivered between 1/1/2010
and 10/8/2015 was generated by linking electronic health record data from 21 Missouri Federally Qualified Health
Centers (FQHCs) with Medicaid administrative claims. Screening rates for diabetes were calculated within 12 weeks
and 1 year of delivery. Initial screening after the first postpartum year was also documented.
Results: Median age in the final population was 28 (IQR 24–33) years with over-representation of black non-
Hispanic and urban women. In the final population, 9.7% of women had a recommended diabetes screening test
within 12 weeks and 18.9% were screened within 1 year of delivery. An additional 125 women received
recommended screening for the first time beyond 1 year postpartum. The percentage of women who had a
postpartum visit (83.9%) and any glucose testing (40.6%) in the first year far exceeded the proportion of women
with recommended screening tests.
Conclusions: Linking electronic health record and administrative claims data provides a more complete picture of
healthcare follow-up among low income women after gestational diabetes. While screening rates are higher than
reported with claims data alone, there are opportunities to improve adherence to screening guidelines in this
population.
Keywords: Gestational diabetes, Postpartum screening, Care transition, Healthcare access, Medicaid
Introduction
More than half of women with gestational diabetes de-
velop type 2 diabetes, with most cases occurring within
5–10 years of the index pregnancy [1, 2]. Additionally,
gestational diabetes prevalence is highest among racial
and ethnic minorities and women of lower socioeco-
nomic status [3]. Furthermore, while Asian women are
more likely to have gestational diabetes, black and
Hispanic women are more likely to progress to type 2
diabetes [4]. Following gestational diabetes, both the
American Diabetes Association (ADA) and the Ameri-
can Congress of Obstetricians and Gynecologists
(ACOG) recommend screening for type 2 diabetes at
4–12 weeks postpartum with a fasting plasma glucose
(FPG) or 2 h oral glucose tolerance test (oGTT) and
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screening with either of these tests or a hemoglobin
A1C (HbA1C) every 1–3 years thereafter [5, 6].
Existing data on screening rates among low income
women are limited. A study of 6239 women utilizing
South Carolina Medicaid claims data suggested that
screening with a recommended test (FPG or oGTT) oc-
curred in only 3.2% of cases between 5 and 13 weeks
postpartum [7]. Another claims data study including
2367 women on Medicaid in Maryland found screening
with any glucose test occurred in 5.7% of women by 12
weeks and 15.2% by 1 year [8]. These studies likely
underestimate screening in this population, given vari-
able Medicaid income eligibility criteria before, during,
and after pregnancy. In Missouri, many women become
eligible for Medicaid during pregnancy but lose compre-
hensive coverage 60 days after delivery. In fact, most
existing data in the US on screening for type 2 diabetes
after a pregnancy with gestational diabetes come from
large integrated health systems, single centers, and
claims data [7–14]. Fragmentation of care between
health systems prevents follow-up of screening over
time. Additionally, women receive prenatal and postpar-
tum care in clinics and often deliver in hospitals. Asses-
sing screening time frames post-delivery is difficult if
inpatient and outpatient systems are not integrated.
Moreover, there are no published data on screening for
type 2 diabetes that occurs beyond the first postpartum
year.
To better understand healthcare utilization and
screening among low income women, addressing a crit-
ical gap in the literature, we sought to leverage the
strengths of electronic health record (EHR) data and
Medicaid claims data to create a unique linked dataset
with information on prenatal care through delivery into
the postpartum period. We did not limit our data collec-
tion to only the first postpartum year, and we incorpo-
rated variables describing the neighborhood food and
built environment that could have relevance to diabetes
screening and prevention. In this manuscript, we de-
scribe our procedure for creating this novel data re-
source and report population estimates for postpartum
screening according to guideline recommendations.
Methods
Data from most Federally Qualified Health Centers
(FQHC) in Missouri flow into a central data repository.
Health centers that are members of the Missouri Pri-
mary Care Association (MPCA) use different EHR sys-
tems, thus all data enters a data warehouse, managed by
Azara Healthcare, and is mapped to standardize report-
ing across fields. Our study was reviewed and approved
by the Washington University Human Research Protec-
tion Office in October 2015. The Data Use Agreement
with the MPCA was fully executed in April 2016,
defining how the data would be used and specifying pre-
cautions for storing and transferring the data securely.
Twenty six of 29 health center systems gave permission
for their data to be utilized. Data in the final population
of women with gestational diabetes came from 21 health
center systems.
Figure 1 provides an overview of the inclusion criteria
for the population definition procedure. In July 2016, an
initial de-identified dataset was transferred from Azara
Healthcare to investigators at Washington University.
Azara Healthcare generated random number IDs for
each patient in this dataset and included any woman
with an International Classification of Diseases, Clinical
Modifications versions 9 or 10 (ICD-9/10-CM) diagnosis
code or Current Procedural Terminology, 4th edition
(CPT-4) code related to pregnancy care in her record
between January 1, 2010 and December 31, 2015. Files
contained age, race, ethnicity, primary language, patient
encounters (date, time, provider name and type (if docu-
mented), health center, vital signs, height, weight),
charges, payer information, medications and supplies, la-
boratory data, infant birthweight, and delivery date (if
available). However, the clinic EHR data was incomplete
in regard to delivery date as well as administrative codes
for pregnancy comorbidities and delivery complications.
Therefore, we linked EHR data with Medicaid claims
to obtain additional data on pregnancy comorbidities
and delivery complications and to define an accurate de-
livery date for assessing postpartum screening time
frames and marking the gestational period. First, we de-
fined ‘potential gestational diabetes candidates’ utilizing
criteria for abnormal glucose. This was intentionally
broad to be most sensitive in identifying all potential in-
dividuals with glucose abnormalities who may have had
gestational diabetes during pregnancy. Criteria for the
gestational diabetes candidate subset (8008 women) are
defined in Fig. 1.
We further narrowed the gestational diabetes candi-
date subset to those with probable gestational diabetes
using claims data. The random number IDs for each pa-
tient in the gestational diabetes candidate subset were
returned to Azara Healthcare. Identifiers on this subset
were securely transferred from Azara Healthcare to the
Office of Social and Economic Data Analysis (OSEDA)
at the University of Missouri (the state contractor for
Medicaid data) for linkage with Medicaid claims data for
each individual. Claims data included inpatient and
outpatient claims with medical eligibility code, place of
service code, revenue codes, provider specialty code,
National Provider Identifier, provider type code, and
dates of service with ICD-9/10-CM diagnosis, ICD-9-
CM/ICD-10-Procedure Coding System (PCS) procedure
codes, and CPT-4 codes. Data were linked based upon
Medicaid identifier or, if Medicaid identifier was not
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available, a ‘fuzzy match’ process with name, date of
birth, zip code and phone number was used. Once
linked, OSEDA stripped all HIPAA identifiers from the
data, retaining only the previously generated random
number ID, and transferred this linked file to investiga-
tors at Washington University. There were 6402 women
in this linked dataset (91% of whom were successfully
linked via Medicaid identifier). Address was separately
transferred to investigators in conjunction with the
randomly generated ID for geographic analyses. No
clinical information attached to HIPAA identifiers was
transferred between entities, minimizing the risk to
confidentiality. Figure 2 illustrates the flow of data
from different sources.
Medicaid claims were utilized to most accurately define
the delivery date as the provider or facility date associated
with a CPT-4 or ICD-9/10-CM or PCS code for delivery.
In order to identify this date, a hierarchical algorithm was
implemented.: 1) facility and provider claims with CPT-4
or ICD 9/10 code for delivery during an inpatient admis-
sion; 2) CPT-4 or ICD9/10 code for delivery and an add-
itional code for delivery-related diagnosis or procedure; 3)
CPT-4 or ICD 9/10 code for delivery and a provider claim
for anesthesia/epidural; 4) CPT-4 or ICD9/10 code for de-
livery and a provider claim for postpartum care following
birth; or 5) 3 or more delivery-specific codes (including
pathologic examination of the placenta and revenue code
for labor room (720–724, 729)). The majority of deliv-
ery dates (86%) were identified using the first 2 steps in
the algorithm. Of the 6402 women in the linked data-
set, the full algorithm identified at least one delivery
date for 5040 women. For delivery identification codes,
Fig. 1 Creation of the linked Medicaid-EHR retrospective study population. * ICD9: 640–679, V22-V27, V91; ICD10: O09, Z34, Z37, Z39, O10-O16,
O20-O26, O28-O36, O40-O48, O60-O77, O80, O82, O85, O86, O87-O92, O94, O98-O99, O9A, Z3A, A34; CPT: 59400, 59409, 59410, 59412, 59414,
59425, 59426, 59430, 59510, 59514, 59515, 59525, 59610, 59612, 59614, 59618, 59620, 59622, 76801, 76802, 76805, 76810–76821, 76825-76828,
59025. † One or more: fasting glucose > 5.27 mmol/L, Glucose Challenge Test or single 1 h glucose > 7.21 mmol/L, 1 h glucose > 9.99 mmol/L if a
2 and 3 h glucose were recorded on same day, 2 h glucose > 8.6 mmol/L, 3 h glucose > 7.77 mmol/L, A1C > 6.0% (42 mmol/mol), random
glucose > 7.21 mmol/L, Any + urine glucose. ‡ Fuzzy match utilized first name, last name, date of birth, zip code and phone number to match
Azara record with Medicaid record if no Medicaid identifier available. §Algorithm to identify deliveries: 1) facility and provider claims with CPT-4 or
ICD 9/10 code for delivery during an inpatient admission; 2) CPT-4 or ICD9/10 code for delivery and an additional code for delivery-related
diagnosis or procedure; 3) CPT-4 or ICD 9/10 code for delivery and a provider claim for anesthesia/epidural; 4) CPT-4 or ICD9/10 code for delivery
and a provider claim for postpartum care following birth; or 5) 3 or more delivery-specific codes (including pathologic examination of the
placenta and revenue code for labor room (720–724, 729)). || This is the strictest definition for inclusion: ICD-9/10CM code for gestational diabetes
in pregnancy (648.8x, O24.4x) or 2 or more abnormal values on 3 h oGTT by Carpenter and Coustan Criteria: Fasting glucose > 5.27 mmol/L, 1 h
glucose > 9.99 mmol/L, 2 h glucose > 8.6 mmol/L, 3 h glucose > 7.77 mmol/L. Deliveries after 10/8/2015 were excluded to allow everyone the
opportunity for 84 days (12 weeks) post-delivery records
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(see Additional file 1: Table S1 and Additional file 2:
Table S2). This procedure mirrored a previously
validated algorithm for identifying deliveries using ad-
ministrative data [15].
The conception date was defined as 280 days (40 weeks)
prior to the delivery date, based upon the standard gesta-
tional period. The time frame between the conception date
and delivery date was used to identify gestational diabetes
and pregnancy comorbidities and exclude pre-existing dia-
betes. The time before the conception date was used to
identify pre-existing diabetes for exclusion as well. The
strictest definition was applied so that a woman was only
included in the final population as having probable gesta-
tional diabetes if she had an ICD-9/10-CM diagnosis code
for gestational diabetes during the period from conception
to delivery or a documented laboratory diagnosis by
Carpenter and Coustan criteria on a 3 h oral glucose toler-
ance test during pregnancy (n = 1078). These are standard
criteria for diagnosis of gestational diabetes if 2 or more of
the following conditions are true: fasting glucose > 5.27
mmol/L, 1 h glucose > 9.99mmol/L, 2 h glucose > 8.60
mmol/L, 3 h glucose > 7.77mmol/L. Figure 1 further delin-
eates inclusion and exclusion criteria. The first birth per
woman coded for gestational diabetes with no evidence of
pre-existing diabetes served as the index delivery. As the
primary outcome was receipt of recommended screening
by 12 weeks postpartum, individuals with deliveries after
October 8, 2015 were excluded as they would not have had
the full opportunity to achieve the primary outcome.
For the final population, demographic data including
age at delivery, race, ethnicity, and preferred language
were available from EHR records. Height and weight to
Fig. 2 Diagram of flow and type of data from each source. 1a) EHR data flows from MPCA member health centers to central data repository with
Azara Healthcare; 26 health centers approved use of data for this study. 1b) Claims data flows from Missouri Medicaid (fee for service and
managed care plans) to the Office of Social and Economic Data Analysis (OSEDA). 2) De-identified EHR data from women with pregnancy related
codes 1/1/2010–12/31/2015 sent to Washington University (demographics, encounter data, charges, payer information, medications/supplies
ordered, laboratory data, infant birthweight (if available), and delivery date (if available) - delivery date and codes related to comorbidities and
complications were limited. 3) Potential gestational diabetes candidates identified based on combination of ICD-9/10-CM codes, medication and
supply data, laboratory data, and infant birthweight – randomly generated number ID for potential gestational diabetes candidates transferred
back to Azara Healthcare. 4) Azara Healthcare transferred Medicaid identifier, first name, last name, date of birth, zip code and phone number
with randomly generated number ID to OSEDA for linking with claims data from ‘potential gestational diabetes candidates’ with delivery date 1/
1/2010–12/31/2015; Address on these individuals was transferred separately to Washington University for creation of geographic variables. 5)
OSEDA transferred randomly generated number ID with linked inpatient and outpatient claims to Washington University (included medical
eligibility code, place of service code, revenue codes, provider specialty code, National Provider Identifier, provider type code, and dates of service
with ICD-9/10-CM diagnosis, ICD-9-CM/ICD-10-Procedure Coding System (PCS) procedure codes, and CPT-4 codes). 6) Washington University
narrows the population to women with probable gestational diabetes defined by ICD-9/10-CM code or Carpenter and Coustan laboratory criteria
based on defining delivery date, period of gestation, and postpartum period
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calculate BMI prior to the index delivery were missing
on the majority of the population and are not reported.
Home address from EHR records was geocoded using
ESRI ArcGIS (Redlands, CA). This information was then
associated with a census tract and linked to census tract
level variables. These variables included modified retail
food environment index (mRFEI), Rural Urban Con-
tinuum Codes (RUCC), and access to public transporta-
tion. The mRFEI is a measure developed by the Centers
for Disease Control and Prevention (CDC) in 2011 and
calculated as follows: 100* (healthy retailers/(unhealthy
retailers + healthy retailers)) [16]. Higher scores on this
scale represent better access to healthy food. This index
classified healthy retailers as supermarkets and large gro-
cery stores, fruit and vegetable markets, and warehouse
clubs while unhealthy retailers included small grocery
stores, convenience stores, and fast food restaurants.
The RUCC from 2013 are defined by census tract and
are publicly available [17]. Classification ranges from 1
to 9, defining census tracts according to metropolitan,
non-metropolitan urban, and rural areas by population.
Individuals were considered to live near public transpor-
tation if they lived in a city with bus and/or train routes,
as determined by their zip code of residence. The driving
distance in kilometers from a woman’s home to nearest
health center was also calculated.
Pregnancy comorbidities and delivery complications
were defined exclusively using Medicaid claims data as
this information was incomplete in EHR records. Specific
administrative codes were used to identify each comorbid-
ity or complication (see Additional file 1: Table S1). A
pregnancy-specific comorbidity index was calculated using
a previously validated algorithm [18]. Healthcare
utilization metrics including number of prenatal visits to a
healthcare facility, prenatal visits to a certified diabetes
educator (CDE), and number of postpartum visits to a
healthcare facility were calculated utilizing EHR encoun-
ters and CPT-4 codes from the Medicaid claims data.
Completion of screening tests for diabetes in the postpar-
tum period was recorded by type of test and time frame.
These tests were identified utilizing lab names and results
from the EHR or CPT-4 codes from Medicaid claims data.
Screening rates were defined as a percent of the final
population (n = 1078) for FPG, oGTT, HbA1C, and any
glucose test within 12 weeks of delivery and from 12weeks
to 1 year postpartum. Screening rates for recommended
tests (FPG or oGTT within 12 weeks postpartum and FPG,
oGTT, HbA1C after 12 weeks postpartum) were also re-
ported. As some women received multiple screening tests,
the unique number and percent of women screened within
the first postpartum year and at any point after delivery
were also described. Among those who had more than 1
year of postpartum data (n = 672), the number and per-
cent of women receiving a first screening test more than
1 year after delivery were calculated. All data management
procedures and analyses were conducted using SAS Enter-
prise Guide v. 7.1 (Cary, NC).
Results
The median age at delivery for women in the final gesta-
tional diabetes population (n = 1078) was 28 (IQR 24–33)
years, and 19.6% of the population was advanced maternal
age (> 35 at delivery). Self-reported racial or ethnic minor-
ities comprised over half of the population with 40.6% of
women identifying as black non-Hispanic. Preferred lan-
guage other than English was reported in 17.9% of the
population (with an additional 12.3% not reporting a
preferred language), reflecting the large immigrant and
refugee populations served by some of the health centers.
The majority of the population (69.2%) lived in a metro-
politan area with a population > one million, with only
13% living in areas with a population under 20,000 people.
The median distance from home to the closest health cen-
ter was 4.7 km (IQR 2.2–10.4), and 69.5% percent of the
population lived near public transportation. There were
no healthy food retailers according to the mRFEI in the
census tract of residence for 18.9% of the population.
In our final population, 72.1% of the women had a
comorbidity index of 1 or higher and 15.6% had a co-
morbidity index of 4 or higher. This pregnancy specific
comorbidity index was initially developed in an external
cohort of women on Medicaid in pregnancy. In that cohort,
less than 50% of the population had a score of 1 or higher
and each additional point increased the risk of maternal
end organ injury or death within 30 days of delivery by 37%
(95% CI 35–39%) [18]. Hence, our population was relatively
complicated for a pregnant population. Pre-existing or
transient gestational hypertension were among the most
common comorbidities, affecting 21% of the population to-
gether. Additionally, 10.5% of women had mild or severe
pre-eclampsia. One or more codes for depression were
present in 21.4% of the population before or after delivery.
In regard to delivery complications, 23.9% of women had a
Cesarean section in a prior pregnancy and 34.2% of
women had a Cesarean section to deliver the index
pregnancy. Table 1 summarizes demographics, comor-
bidities, and pregnancy and delivery complications.
We next address access to care and adherence to
screening guidelines. Seventy three percent of women
had a visit to a healthcare facility (documented in either
the EHR or Medicaid claims files) in the first 12 weeks
postpartum, and 83.9% had a visit within the first post-
partum year. The median number of prenatal visits doc-
umented in either the EHR or Medicaid claims files was
11.5 (IQR 7–16), and the median number of postpartum
visits was 3 (IQR 1–5). Visits in both the prenatal and post-
partum time frames could have included visits with a
nurse, nurse practitioner, physician’s assistant, or physician,
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as documentation of billing provider in both Medicaid and
EHR data was incomplete. Ten percent of the population
was on an oral hypoglycemic medication during pregnancy
and 2.5% of women were on insulin. For the protocol used
to identify medication type in EHR data, (see Additional
file 3: Table S3). Twelve percent of women received at least
one prenatal visit with a certified diabetes educator.
Twenty one percent of the population had a subsequent
pregnancy during the study period. Median follow-up for
the final population until subsequent pregnancy concep-
tion date or last visit date in either EHR or Medicaid claim
files was 1.2 years (IQR 0.3–2.5). For those with more than
1 year of data (n = 672), median follow-up time until next
pregnancy conception date or last visit date was 2.1 years
(IQR 1.3–3.3). Table 2 details healthcare utilization in the
final gestational diabetes population.
Table 3 depicts screening rates by type of test and time
frame. For the primary outcome, 105 women (9.7% of
the total population) received a recommended test (FPG
or oGTT) to screen for type 2 diabetes by 12 weeks post-
partum. By 1 year postpartum, 204 women (18.9% of the
total population) had received a recommended test
(HbA1C (if done after 12 weeks), FPG, or oGTT). Of the
whole population, 329 women (30.5%) received at least
one recommended screening test during the study
period and before a subsequent pregnancy. After 12
weeks postpartum, the most common recommended
screening test was an HbA1C. At all times points, it was
more common to have any glucose test completed than
it was to have a recommended test. Any glucose test
could include a random blood or urine glucose or a glu-
cose on a complete or basic metabolic panel or renal
function panel. More than 1 year of follow-up data were
Table 1 Demographics, geographic data, and clinical
characteristics of low income women with gestational diabetes
in Missouri (n = 1078)
Demographics Median (IQR)
or n(%)
Age at delivery 28 (24–33)
Advanced maternal age (35 + at delivery) 211 (19.6)
Race/ethnicity
White non-Hispanic (or ethnicity unreported) 338 (31.4)
Black non-Hispanic (or ethnicity unreported) 438 (40.6)
Hispanic 168 (15.6)
Asian 45 (4.2)
Other (Native American, Pacific Islander,
More than one Race)
37 (3.4)
Missing/Unreported 52 (4.8)
Preferred Language other than English 193 (17.9)
Preferred Language not available 133 (12.3)
Geographic dataa
Residence in county with metropolitan
area > one million (n = 1044)
722 (69.2)
Lived near public transportation (n = 1063) 739 (69.5)
Distance from home to nearest health
center (km) (n = 1041)
4.7 (2.2–10.4)
Modified retail food environment index
(mRFEI) by census tractb (n = 1053)
9.1 (4.8–14.3)
Census tract of residence had no healthy
food retailers by mRFEI (n = 1053)
199 (18.9)
Selected comorbidities and pregnancy complicationsc
Pregnancy specific comorbidity index ≥ 1d 777 (72.1)
Drug abuse 55 (5.1)









Mild pre-eclampsia 63 (5.8)
Severe pre-eclampsia/Eclampsia 50 (4.6)
Selected delivery complicationse
C-section (prior pregnancy) 258 (23.9)
C-section (this pregnancy) 369 (34.2)
Induction 340 (31.5)
Cord complication 140 (13.0)
Chorioamnionitis 112 (10.4)
Preterm labor 80 (7.4)
Abnormal forces of labor 66 (6.1)
Table 1 Demographics, geographic data, and clinical
characteristics of low income women with gestational diabetes




Obstruction of labor without dystocia 48 (4.5)
Shoulder dystocia 40 (3.7)
aMissing geographic data resulted from inability to match to home address to
geocode, out of state address listed, or missing clinic information
b Per the CDC, mean mRFEI in Missouri and nationally is 10
c Other comorbidities present in less than 5% of the population: congenital
heart disease, congestive heart failure, ischemic heart disease, human
immunodeficiency virus (HIV), alcohol abuse, pulmonary hypertension, chronic
renal disease, sickle cell disease, systemic lupus erythematosus, cardiac valve
disease, multiple gestation
d In the validation cohort for the comorbidity index, developed in a Medicaid
population, less than half the population had a score of 1 or higher. Each
additional point increase in comorbidity index was associated with a 37%
increase (95% CI 1.35–1.39) in maternal end organ injury or death from
delivery to 30 days postpartum
e Other delivery complications present in less than 5% of the population:
fetopelvic disproportion, postpartum hemorrhage, placenta previa, placental
abruption, other delivery infection, hypotension, severe laceration
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available on a subset of women (n = 672). In this group,
125 women (18.6% of the subset) completed a first rec-
ommended screening test more than 1 year after the
index delivery.
Given the possibility of loss of Medicaid coverage after
60 days postpartum, we examined how screening tests
were identified in different time frames (CPT codes
came from Medicaid claims and laboratory data came
from EHR files). In the first 12 weeks postpartum, it was
more common for labs to be identified by CPT code
than EHR laboratory data. After 12 weeks postpartum, it
was more common for tests to be identified with EHR
laboratory data than CPT code data. For the CPT codes
used to identify visits and screening tests, (see Additional
file 2: Table S2).
Discussion
To our knowledge, this is the first time that statewide
EHR data from FQHCs has been linked to Medicaid
administrative claims data to provide population esti-
mates of follow-up care among women with gestational
diabetes covered by Medicaid during pregnancy. This
linked dataset allows us to more comprehensively study
a population that is understudied because of fragmenta-
tion of care and loss of health insurance after pregnancy.
During the study period, Medicaid income eligibility in
Missouri was 185–200% of the federal poverty level
(FPL) during pregnancy and 22–37% of the FPL for par-
ents after pregnancy [19]. Utilizing the FQHC EHR data
allowed us to continue to follow these women after they
were no longer covered by Medicaid. Likewise, the
Medicaid claims data provided comprehensive delivery
information that was unavailable in the clinic record.
Through leveraging the strengths of each data source,
we present a more complete picture of healthcare for
these women. Given that all FQHCs have to report some
data to the federal government for the Uniform Data
Set, it is possible that this analysis could be replicated in
other states through the data vendors for their primary
care associations.
Our population is representative of women in Mis-
souri receiving care in FQHCs on Medicaid during preg-
nancy and as free from bias as possible given the study
design and data sources. When compared with publicly
Table 2 Healthcare utilization among low income women with
gestational diabetes in Missouri (n = 1078)
Prenatal healthcare utilization Median (IQR)
or n (%)
Oral hypoglycemic medicine prescribed
during pregnancy
108 (10.0)
Insulin prescribed during pregnancy 27 (2.5)
Total visits during prenatal period a 11.5 (7–16)
Time from first prenatal visit to delivery
(weeks) (n = 1065)
29.7 (23.0–33.1)
Women with ≥ one prenatal CDE visits 130 (12.1)
Women with no medical records available
prior to prenatal record
395 (36.6)
Postpartum maternal healthcare utilizationb Median (IQR)
or n (%)
Total visits within one year postpartum a 3 (1–5)
Women with at least one visit in first
12 weeks postpartum a
787 (73.0)
Women with at least one visit in the first
postpartum year a
904 (83.9)
Postpartum data available for ≥ one year 672 (62.3)
Length of follow-up for whole population
(years) c
1.2 (0.3–2.5)
Length of follow-up for individuals
with > one year of data (years) c
2.1 (1.3–3.3)
a These include any visit to a healthcare facility present in either the Medicaid
file, EHR file, or both. These can include nurse visits, but do not include CDE
visits or visits with a registered dietician (RD)
b These are maternal care visits only (newborn care was not linked). If another
pregnancy occurred within the first postpartum year, this represents
postpartum visits prior to conception date for next pregnancy
c Time in years between delivery of index pregnancy and estimated
conception date for next pregnancy or last visit date
Table 3 Postpartum diabetes screening rates among low income women with gestational diabetes in Missouri








Whole Population (n = 1078)
Screened 0–12 weeks postpartumd 39 (3.6) 78 (7.2) 49 (4.6) 105 (9.7) 293 (27.2)
Screened 12 weeks- one year postpartum d 16 (1.5) 15 (1.4) 107 (9.9) 121 (11.2) 246 (22.8)
Screened by one year postpartum (unique) 55 (5.1) 92 (8.5) 141 (13.1) 204 (18.9) 438 (40.6)
Screened at any time from delivery to next
pregnancy/last follow-up (unique)
75 (6.9) 107 (9.9) 272 (25.2) 329 (30.5) 575 (53.3)
Women with > one year follow-up data (n = 672)
1st screening test done >one year postpartum 20 (3.0) 15 (2.2) 131 (19.5) 125 (18.6) 137 (20.4)
aFPG = fasting plasma glucose; 2hoGTT = 2 h oral glucose tolerance test; HbA1C = hemoglobin A1C
b Recommended = FPG or 2hoGTT in first 12 weeks; FPG, oGTT, or HbA1C after 12 weeks
c Includes random blood or urine glucose, complete metabolic panel, basic metabolic panel, renal function panel, and all recommended tests
d There are some women who were screened both within 12 weeks and between 12 weeks and 1 year postpartum
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available information from the Uniform Data Set, for the
centers that consented to use of their data, the number
of women included in our population from each health
center was generally proportional to the number of pre-
natal patients delivered at each center during the study
period. The racial and ethnic composition of our popula-
tion was comparable to that expected from publicly re-
ported data on the patient populations served at the
included health centers.
We demonstrated higher screening rates for women
receiving Medicaid during pregnancy than exhibited
in analyses that used administrative claims data alone
[7, 8]. We found that 9.7% of our population received
a recommended screening test by 12 weeks postpartum
(8.4% if restricted to 4–12 weeks postpartum), as com-
pared with 3.2% in South Carolina Medicaid claims.
Twenty seven percent of our population had any glucose
test at 12 weeks and 40.6% had any glucose test by 1 year
postpartum, as compared with 5.7 and 15.2% in a Mary-
land Medicaid claims population. Moreover, 18.9% of our
population had received a recommended test by 1 year
postpartum, and 30.5% received a recommended screen-
ing test at any point after delivery and before a subsequent
pregnancy. While this is lower than screening rates re-
ported in privately insured populations and integrated
health systems, [10, 20, 21] our population’s ability to re-
ceive optimal follow-up care is complicated by challenges
with healthcare access, fragmented care delivery, and
other social determinants of health.
Our results show that there are clear opportunities for
increasing glucose screening in this population. A major-
ity of women had a visit to a healthcare facility in the
postpartum period (73% by 12 weeks and 83.9% by 1
year). Even if we assume that many of the women who
had a visit received an order for screening that was not
completed, the gap between the number of women with
a recommended test and the number of women with
any glucose test represents a window of opportunity for
increasing screening. Twice as many women received
any glucose test (22.8%) as received a recommended test
(11.2%) between 12 weeks and 1 year postpartum. As
women are getting labs completed for other purposes,
and the HbA1C is a non-fasting test, it is possible to in-
crease screening through this modality in the time frame
after 12 weeks postpartum.
Another strength of our population is the racial and
ethnic diversity, with 40.6% black non-Hispanic women.
In many other large studies of postpartum screening,
black women have traditionally been under-represented
as compared to their proportion of the US population
and other racial and ethnic groups [10, 12, 21–25]. Our
study adds additional screening data to the literature in
this group at high risk for progression to type 2 diabetes
[4]. Further, our study reports on screening that occurs
more than 1 year after delivery, which is unique to the
literature. This is important because it appears that
women continue to receive screening after 1 year post-
partum, even if they have not been previously screened.
Women may be more able to prioritize their health after
adapting to the demands of childcare in the first year.
Some of these later screening tests may occur inciden-
tally when women present for other healthcare needs.
Finally, we were able to incorporate geographic data on
our population, including distance from home to nearest
clinic, neighborhood food environment, and proximity of
public transportation. These factors may affect follow-up
care, diabetes screening and diabetes prevention but have
not been examined in prior literature.
Our study has a number of limitations. First, we were
only able to assess completed or billed laboratory tests
and did not have data on all ordered tests. If a laboratory
test was not mapped in the central data warehouse or
not billed to Medicaid, we would not have captured it.
However, we were able to capture at least some point of
care glucose and HbA1C measures, in addition to trad-
itional labs, in the central data warehouse. Further, while
we could capture screening billed to Medicaid from all
sites (FQHC and other) while a woman was still receiv-
ing Medicaid, screening after Medicaid lapsed was only
available through our FQHC sites. However, as our
FQHCs provide essential care for uninsured women and
our population was initially identified as receiving care
in FQHCs, it is a reasonable assumption that the major-
ity of care for our population would continue to occur
in this setting.
We also had no data prior to the prenatal record for
36.6% of women. This is not surprising given that pre-
ventive care is often foregone among patients with few
resources. Additionally, for 119 women who delivered
before October 10, 2010, we did not have the opportun-
ity for a full 280 day prenatal care record. Hence, we
may have missed comorbidities or prenatal visits in these
women. For the 164 women that delivered in 2015, we
did not have the opportunity to capture a full postpar-
tum year and may have missed postpartum screening
between 12 weeks and 1 year in this subset; however, ex-
cluding these women did not affect screening estimates
substantially. For prenatal CDE visits, we were only able
to document billed visits. If these visits were not billed
by the health center or if the health center provided dia-
betes education with a non-CDE provider, this would
not be captured. This is important to note as many
health centers are not able to maintain a CDE on staff.
While we have identified visits to a healthcare facility in
both prenatal and postpartum time frames, it was diffi-
cult to differentiate between nurse visits and visits with
a doctor, nurse practitioner, or physician’s assistant. We
did assess the Medicaid claims files for visits that had
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CPT codes that were level 3 or higher (99203-99205 or
99213-99215) as these are less likely to be nurse-only
visits. In the prenatal time frame, the median number of
level 3 or higher visits was 5 (IQR 2–9). Level 3 or
higher visits were very infrequent in the postpartum
time period. Given bundled billing for prenatal and post-
partum care, this method likely under-counts visits with
a provider.
There were three FQHC systems serving predomin-
antly rural populations that did not approve release of
their data, leading to over-representation of urban areas
in our study population. Additionally, if some centers
were better at coding gestational diabetes diagnoses and
having laboratory data sent to the centralized data ware-
house, we were not able to eliminate that potential bias.
While we sought to incorporate clinical data where pos-
sible, height, weight, and BMI were available on less than
half of the women and are not reported. We utilized ad-
ministrative codes to identify comorbidities and compli-
cations as well as some of the laboratory tests completed
for screening. This limitation is mitigated by the fact
that many of these codes have been validated in prior
studies [15, 18, 26–30]. Medication and supply data were
available from the EHR, but not in our administrative
claims data. We may have missed oral hypoglycemic
therapy or insulin that was added to a patient’s regimen
if care was transferred from an FQHC to a specialty cen-
ter during pregnancy. However, published data suggest
that 70–85% of women with gestational diabetes can be
managed without medication, so our finding of 12.5% of
our population on medication during pregnancy may
not underestimate medication use substantially [5]. Fi-
nally, while our data is only a subset of the Missouri
Medicaid population with gestational diabetes during
this time frame, there is a depth of information avail-
able in this population that is absent from previously
published work.
Conclusions
By utilizing EHR data linked to Medicaid claims data,
we have documented that screening for type 2 diabetes
after a pregnancy with gestational diabetes occurred in
our predominately urban population at rates higher
than previously reported in Medicaid claims data alone.
However, there are opportunities for increasing screen-
ing at all time points. Additionally, documentation of
screening after the first postpartum year is important as
the risk for developing type 2 diabetes is lifelong. Fur-
ther analysis of this data will examine individual, health
system, and societal factors associated with lack of
screening to inform interventions that close the gap be-
tween current practice and guideline recommended
screening.
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